SANTA FE, N.M., March 27, 2006 (PRIMEZONE) -- CytoDyn, Inc. (OTCBB:CYDY) has applied for the trademark Formaxycin(tm) (fer-MAX-uh-sin) to brand its new cancer drug. Like several approved cancer drugs, Formaxycin(tm) cannot be synthesized from scratch but must be extracted from a plant. A classic example of this class of antineoplastic agents is the Vinca alkaloids. These drugs, which come from the Madagascar periwinkle (Catharanthus roseus), include vinblastine and vincristine. Both are used to treat Hodgkin's and other lymphomas.
CytoDyn is currently negotiating for a contract cGMP manufacturer to produce Formaxycin,(tm) which is in preclinical development. There is no guarantee that the trademark will be registered nor that development of the drug will be successful.
Visit our website at www.cytodyn.com for more information.
The CytoDyn, Inc. logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=2461